Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Beigene Ltd ADR
(NQ:
BGNE
)
208.03
+0.78 (+0.38%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
322,583
Open
208.13
Bid (Size)
187.44 (1)
Ask (Size)
217.00 (2)
Prev. Close
207.25
Today's Range
205.62 - 209.99
52wk Range
126.97 - 248.16
Shares Outstanding
1,211,067,023
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024
Today 9:05 EST
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Mourns Death of Beloved Board Member Donald Glazer
October 28, 2024
From
BeiGene, Ltd.
Via
Business Wire
Performance
YTD
+17.53%
+17.53%
1 Month
-14.40%
-14.40%
3 Month
+25.58%
+25.58%
6 Month
+28.03%
+28.03%
1 Year
+6.06%
+6.06%
More News
Read More
Expert Outlook: BeiGene Through The Eyes Of 4 Analysts
October 22, 2024
Via
Benzinga
BeiGene Receives Positive CHMP Opinions for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma
October 21, 2024
From
BeiGene, Ltd.
Via
Business Wire
What Analysts Are Saying About BeiGene Stock
September 18, 2024
Via
Benzinga
BeiGene Highlights Waldenström’s Macroglobulinemia Innovation at IWWM 2024
October 16, 2024
From
BeiGene, Ltd.
Via
Business Wire
US Listed Chinese Stocks Dominate Another Week - Li Auto, JD.com Among Top 10 Large Cap Gainers Last Week (Sept 30-Oct 4): Are The Others In Your Portfolio?
October 06, 2024
Via
Benzinga
Active Biotech Alert: FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket
October 04, 2024
Via
FinancialNewsMedia
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Product Safety
Top 2 Health Care Stocks That May Plunge In August
August 26, 2024
Via
Benzinga
BeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, including TEVIMBRA®, for Treatment of ESCC and Gastric/GEJ Cancers
September 26, 2024
From
BeiGene, Ltd.
Via
Business Wire
Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors
September 26, 2024
From
BeiGene, Ltd.
Via
Business Wire
FDA Casts Doubt On Use Of Merck, Bristol Myers' PD-1 Cancer Drugs For Certain Type Of Gastric Cancer Patients
September 25, 2024
Via
Benzinga
Exposures
Product Safety
Chinese Biotech BeiGene Labeled 'Unique Investment' As Analyst Confident In Lead Cancer Drug
September 18, 2024
Via
Benzinga
Oxford Industries Reports Weak Results, Joins Viper Energy And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
September 12, 2024
Via
Benzinga
Why Champions Oncology Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
September 12, 2024
Via
Benzinga
BeiGene Announces Updates to Commercial Leadership Team
September 09, 2024
From
BeiGene, Ltd.
Via
Business Wire
Innovent Bio hopes for plus-sized profits from obesity drug
September 06, 2024
Via
Benzinga
Topics
Retirement
Exposures
Pension
Week In Review: UCB Sells China Drug Portfolio To CBC For $680 Million
August 31, 2024
Via
Talk Markets
BeiGene to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
August 28, 2024
From
BeiGene, Ltd.
Via
Business Wire
BeiGene’s BGB-16673 Receives U.S. FDA Fast Track Designation for CLL/SLL
August 26, 2024
From
BeiGene, Ltd.
Via
Business Wire
Cancer Medicines From Merck, Bristol Myers And BeiGene In Question, As FDA Committee To Discuss Limiting PD-1 Drugs For Stomach Cancer
August 23, 2024
Via
Benzinga
Exposures
Product Safety
BeiGene Enters Next Phase of Global Growth with Announcement of Second Quarter 2024 Financial Results and Corporate Updates
August 07, 2024
From
BeiGene
Via
Business Wire
Week In Review: Nanjing Triastek Partners With BioNTech In A $1.2 Billion Drug Development Deal
July 27, 2024
Via
Talk Markets
BeiGene Opens Flagship U.S. Biologics Manufacturing and Clinical R&D Facility, Continues Global Expansion to Deliver Medicines to More Patients Around the World
July 23, 2024
From
BeiGene, Ltd.
Via
Business Wire
AbbVie Could Soar 24%, According to a Wall Street Analyst. Is the High-Yield Dividend Stock a Buy Now?
July 22, 2024
Via
The Motley Fool
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
